188 related articles for article (PubMed ID: 27102929)
1. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
6. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R
Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
[TBL] [Abstract][Full Text] [Related]
10. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Mueller BU; Bennett CM; Feldman HA; Bussel JB; Abshire TC; Moore TB; Sawaf H; Loh ML; Rogers ZR; Glader BE; McCarthy MC; Mahoney DH; Olson TA; Feig SA; Lorenzana AN; Mentzer WC; Buchanan GR; Neufeld EJ; ;
Pediatr Blood Cancer; 2009 Feb; 52(2):259-62. PubMed ID: 18937333
[TBL] [Abstract][Full Text] [Related]
11. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
[TBL] [Abstract][Full Text] [Related]
12. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C
Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
Parodi E; Rivetti E; Amendola G; Bisogno G; Calabrese R; Farruggia P; Giordano P; Matarese SM; Nardi M; Nobili B; Notarangelo LD; Russo G; Vimercati C; Zecca M; De Mattia D; Ramenghi U
Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
[TBL] [Abstract][Full Text] [Related]
16. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
